China's CSRC investigates Kangzhi Pharmaceutical for suspected disclosure violations
On September 18, Kangzhi Pharmaceutical (300086.SZ) announced it received a Notice of Case Filing from the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure regulations. The company stated operations are normal and it will cooperate. This follows an April 2026 Hainan Securities Regulatory Bureau rectification order over inaccurate financial disclosures, non-operational fund occupation of RMB 1.0042 million by its controlling shareholder, and irregular agency sales management. Kangzhi has reported net losses for four consecutive years through 2025.
Editorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page reads the event directly, while its address stays stable when the title changes.
- Summary covers the current reports
Cross-source coverage
Common ground
- The CSRC's escalation from a rectification order to a formal investigation shows China's regulatory system is maturing and getting more thorough.
- Kangzhi Pharmaceutical's four straight years of losses and 37% revenue drop are serious business problems that can't be ignored.
- The Hainan Bureau's on-site inspection caught the fund diversion, which is a positive sign for regulatory enforcement.
Points of contention
- Eastern Agent says the regulator catching the issue proves the system works, while Neutral Agent argues the board failed because it didn't catch it first.
- Eastern Agent sees the million yuan diversion as desperation from a struggling company, but Neutral Agent calls it entitlement from a controlling shareholder who thinks they can take what they want.
- Neutral Agent separates the compliance issue from the business failure, while Eastern Agent insists they're connected and the investigation prevents bigger fraud.
Blind spots
- Both sides focus on the investigation but overlook what the auditor will say in the next annual report—like a going-concern warning or bad opinion on internal controls.
- No one fully addresses whether the controlling shareholder still controls the board, which is the real governance question behind the fund diversion.
- The debate misses the bigger picture: if Kangzhi can't make money and its board can't stop small diversions, should it even be a public company?
WorldAttention’s read
This debate shows that China's securities regulation is getting stronger—the CSRC caught a problem, ordered a fix, and is now digging deeper, which is real progress. But that doesn't let Kangzhi's board off the hook; they missed a million-yuan diversion that a routine inspection found. The company's four straight years of losses and shrinking revenue are the bigger worry, and the investigation is treating a symptom of a broken business, not the root cause. Investors should watch the next audit opinion closely, because that will reveal if the company's internal controls are truly broken. In the end, the system is improving, but Kangzhi's shareholders still have a lot to worry about beyond just the investigation.
Reporting timeline
Kangzhi Pharmaceutical Under CSRC Investigation for Suspected Information Disclosure Violations
On September 18, Kangzhi Pharmaceutical announced it received a Case Filing Notice from the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws and regulations. The company stated its operations are normal and it will cooperate with the investigation. This follows an earlier CSRC Hainan Bureau on-site inspection that found three major issues: inaccurate financial disclosures in 2023 and 2024 annual reports; payment of RMB 1.0042 million in performance wages to controlling shareholder Hainan Hongshi Investment Co., Ltd. employees, constituting non-operational fund occupation; and irregular management of agency sales personnel. The CSRC ordered rectification in April, and the company released a rectification report on April 28, including retrospective accounting corrections, recovery of the occupied funds, and internal control improvements. The company's 2026 semi-annual report showed a 37.67% year-on-year revenue decline to RMB 145 million and a net loss of RMB 32.7665 million, though losses narrowed.
Read sourceChina's CSRC Investigates Kangzhi Pharmaceutical for Suspected Disclosure Violations
Kangzhi Pharmaceutical (300086.SZ) announced on September 18 that it received a Notice of Case Filing from the China Securities Regulatory Commission (CSRC). The CSRC has decided to open an investigation into the company due to suspected violations of information disclosure regulations, in accordance with the Securities Law of the People's Republic of China and the Administrative Penalty Law of the People's Republic of China. The investigation is based on the company's alleged failure to comply with disclosure requirements, though specific details of the suspected violations have not been disclosed. The announcement was made via a stock market news outlet, Gelonghui, and the company is listed on the Shenzhen Stock Exchange.
Read sourceKangzhi Pharmaceutical Under CSRC Investigation for Information Disclosure Violations
Kangzhi Pharmaceutical (Securities Code: 300086) announced on September 18 that it received a 'Notice of Case Filing' from the China Securities Regulatory Commission (CSRC) for suspected violations of laws and regulations regarding information disclosure. The company stated its operations are normal and it will cooperate with the investigation. This follows earlier administrative regulatory measures by the Hainan Securities Regulatory Bureau in April 2026, which ordered rectification for three compliance issues: inaccurate financial information disclosure in 2023 and 2024 annual reports, non-operational fund occupation of RMB 1.0042 million by its controlling shareholder Hainan Hongshi Investment Co., Ltd., and irregular management of personnel in agency sales businesses. The company has since recovered the occupied funds and implemented corrective measures. Kangzhi Pharmaceutical, a pediatric medicine and maternal health products firm listed in 2010, has reported net losses for four consecutive years from 2022 to 2025, with losses deepening to -RMB 230 million in 2025. In the first half of 2026, revenue fell 37.67% year-on-year to RMB 145 million, and net cash flow from operations turned negative. Its stock price closed at RMB 6.27 on September 18, with a market capitalization of RMB 2.854 billion.
Read sourceShow 3 older updatesHide older updates
Kangzhi Pharmaceutical under CSRC Investigation for Suspected Disclosure Violations
On September 18, Kangzhi Pharmaceutical (stock code 300086) announced that it had received a Notice of Case Filing from the China Securities Regulatory Commission (CSRC). The CSRC has decided to open an investigation into the company due to suspected violations of information disclosure laws and regulations. The announcement was reported by People's Finance News and sourced from stockstar_securities_news. The investigation is ongoing, and no further details about the specific nature of the alleged violations have been disclosed at this time.
Read sourceChina's Kangzhi Pharmaceutical Probed by CSRC for Suspected Disclosure Violations
On the evening of September 18, Kangzhi Pharmaceutical issued an announcement stating that the China Securities Regulatory Commission (CSRC) has decided to file a case against the company due to suspected violations of information disclosure regulations. The investigation is being conducted in accordance with laws and regulations including the Securities Law of the People's Republic of China and the Administrative Penalty Law of the People's Republic of China. The announcement was reported by Beijing Business Today and summarized by East Money, a Chinese financial news platform. The investigation marks a regulatory action against the pharmaceutical company for potential non-compliance with disclosure rules, which could lead to administrative penalties if violations are confirmed.
Read sourceKangzhi Pharmaceutical Investigated by CSRC for Suspected Information Disclosure Violations
Kangzhi Pharmaceutical announced on the evening of September 18 that it is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure regulations. The company stated that, as of the date of the announcement's disclosure, its production and business operations are proceeding normally and that the investigation will not have a material impact on its normal activities. During the investigation period, Kangzhi Pharmaceutical said it will actively cooperate with the CSRC and strictly fulfill its information disclosure obligations in accordance with relevant regulations and regulatory requirements. The report was sourced from the China Business Journal and published on East Money's A-share company news section.
Read source